MedTrace Logo

Phase III Trial of Oral Thalidomide in Advanced Hepatocellular Carcinoma With Poor Liver Reserve

NCT00225290 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 230

Last updated 2011-10-12

No results posted yet for this study

Summary

To compare the overall survival of thalidomide- and placebo-treated advanced HCC patients.

Conditions

  • Carcinoma, Hepatocellular

Interventions

DRUG

Thalidomide(Thado)

Sponsors & Collaborators

  • TTY Biopharm

    lead INDUSTRY

Principal Investigators

  • Li-Tzong Chen, M.D Ph.D. · Division of Cancer Research, National Health Research Institute Ward 191

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-02-28

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00225290 on ClinicalTrials.gov